Artis Ventures
Cameron is completing a PhD in the Howarth Lab at the University of Cambridge, UK. His research focuses on engineering highly stable antibody mimetic proteins for action in the gastrointestinal tract. Disease targets of particular interest include the inflammatory pathways involved in IBD, the microbiome, food intolerances and microbial infection. Cameron completed a masters degree in the Biggin Group (University of Oxford) using protein MD simulation and high-throughput fragment-based drug design to inhibit novel cancer targets. He now uses this computational experience to complement protein display technologies for antibody design. Cameron is also involved in growing the new chapter of Nucleate in the UK.
This person is not in the org chart
This person is not in any offices
Artis Ventures
ARTIS Ventures partners with entrepreneurs who are driven to positively impact their world through disruptive technological and scientific innovation, focusing on the intersection of computer science and life science.